March 4, 2024
National Center for Advancing Translational Sciences (NCATS)
The purpose of this Notice is to change the application types allowed in PAR-23-267, Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine, to include Renewal (Phase II) applications.
Part 2. Full Text of Announcement
Section II. Award Information
Currently reads:
Resubmission (All Phases)
New (Phase I)
New (Phase I, Fast-Track)
New (SBIR Direct Phase II)
Corrected to read (in bold italics):
Resubmission (All Phases)
New (Phase I, Fast-Track, Direct Phase II)
Renewal (Phase II)
All other aspects of the NOFO remain unchanged.
Please direct all inquiries to:
Christine Happel, Ph.D.
Office of Special Initiatives
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-9444
Email: [email protected]